Stryker to Acquire Amplitude Vascular Systems for IVL Market Expansion
Stryker has agreed to acquire Amplitude Vascular Systems to enter the intravascular lithotripsy market and broaden its vascular care portfolio. AVS's Pulse IVL system is in a 115-patient POWER PAD 2 IDE trial, and the deal follows Stryker's $4.9bn Inari Medical acquisition.
1. Acquisition Details
Stryker agreed to acquire Amplitude Vascular Systems in an undisclosed transaction, marking its entry into the intravascular lithotripsy (IVL) segment. This move follows its $4.9bn purchase of Inari Medical in February 2025 and supports a broader peripheral vascular growth strategy.
2. Pulse IVL Technology and Clinical Trial
Amplitude’s Pulse IVL system uses pressurized acoustic waves delivered via a balloon catheter to fracture calcium deposits in peripheral arteries. The device received an FDA-granted investigational device exemption and is being evaluated in the POWER PAD 2 trial involving 115 patients with moderate-to-severe calcified peripheral artery disease.
3. Strategic Rationale and Competitive Landscape
The acquisition will complement Stryker’s existing peripheral vascular portfolio and bolster its position against Shockwave Medical, Boston Scientific and Abbott, all targeting the fast-growing IVL market. Entry into this space addresses significant unmet needs in arterial disease treatment.
4. Market Impact and Future Outlook
Upon regulatory approval, Pulse IVL will expand Stryker’s addressable market and diversify its arterial disease offerings. No completion timeline has been announced, but integration is expected to leverage Stryker’s global sales network and clinical expertise.